SI1096937T1 - Ranolazinske formulacije s podaljšanim sproščanjem - Google Patents

Ranolazinske formulacije s podaljšanim sproščanjem

Info

Publication number
SI1096937T1
SI1096937T1 SI9930749T SI9930749T SI1096937T1 SI 1096937 T1 SI1096937 T1 SI 1096937T1 SI 9930749 T SI9930749 T SI 9930749T SI 9930749 T SI9930749 T SI 9930749T SI 1096937 T1 SI1096937 T1 SI 1096937T1
Authority
SI
Slovenia
Prior art keywords
sustained release
release ranolazine
ranolazine formulations
formulations
sustained
Prior art date
Application number
SI9930749T
Other languages
English (en)
Inventor
Andrew A. Wolff
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1096937(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of SI1096937T1 publication Critical patent/SI1096937T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SI9930749T 1998-09-10 1999-09-09 Ranolazinske formulacije s podaljšanim sproščanjem SI1096937T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
EP99948196A EP1096937B9 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations
PCT/US1999/020968 WO2000013687A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (1)

Publication Number Publication Date
SI1096937T1 true SI1096937T1 (sl) 2005-04-30

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
SI9930749T SI1096937T1 (sl) 1998-09-10 1999-09-09 Ranolazinske formulacije s podaljšanim sproščanjem
SI9930078T SI1109558T1 (sl) 1998-09-10 1999-09-09 Ranolazinske formulacije s podaljšanim sproščanjem

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI9930078T SI1109558T1 (sl) 1998-09-10 1999-09-09 Ranolazinske formulacije s podaljšanim sproščanjem

Country Status (33)

Country Link
US (14) US6303607B1 (sl)
EP (3) EP1109558B1 (sl)
JP (2) JP3745621B2 (sl)
KR (1) KR100475759B1 (sl)
CN (2) CN1193757C (sl)
AR (3) AR022085A1 (sl)
AT (2) ATE285774T1 (sl)
AU (4) AU744071B2 (sl)
BR (2) BR9913626A (sl)
CA (2) CA2342390C (sl)
CY (1) CY2008020I2 (sl)
CZ (2) CZ301341B6 (sl)
DE (3) DE69901570T2 (sl)
DK (2) DK1109558T3 (sl)
ES (2) ES2234302T3 (sl)
FR (1) FR09C0001I2 (sl)
GE (1) GEP20053420B (sl)
HK (2) HK1040060A1 (sl)
HU (2) HU224215B1 (sl)
IL (6) IL141892A0 (sl)
LU (1) LU91504I2 (sl)
MX (2) MXPA01002598A (sl)
NL (1) NL300371I2 (sl)
NO (4) NO320986B1 (sl)
NZ (2) NZ510386A (sl)
PL (3) PL202207B1 (sl)
PT (2) PT1096937E (sl)
RU (2) RU2214233C2 (sl)
SI (2) SI1096937T1 (sl)
TR (2) TR200101262T2 (sl)
TW (1) TWI241911B (sl)
UA (2) UA67793C2 (sl)
WO (2) WO2000013686A2 (sl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
EP1259230A2 (en) 2000-02-18 2002-11-27 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
KR101061351B1 (ko) 2002-04-09 2011-08-31 플라멜 테크놀로지스 활성 성분 마이크로캡슐의 경구 현탁액
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP1505977B1 (en) 2002-05-21 2014-09-10 Gilead Sciences, Inc. Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
EP1909767A2 (en) * 2005-07-28 2008-04-16 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
WO2007108362A1 (ja) * 2006-03-17 2007-09-27 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、表示装置および照明装置
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
JP2010518181A (ja) 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010520291A (ja) * 2007-03-07 2010-06-10 コンサート ファーマシューティカルズ インコーポレイテッド 抗狭心症化合物としての重水素化ピペラジン誘導体
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
US20080312247A1 (en) * 2007-06-13 2008-12-18 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
CA2713521A1 (en) * 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
EP2515880B1 (en) 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
NO3175985T3 (sl) 2011-07-01 2018-04-28
JP2014531454A (ja) 2011-09-21 2014-11-27 ギリアード サイエンシーズ， インコーポレイテッド グルカゴン分泌を減少させるナトリウムチャネルブロッカー
WO2014176567A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Pharmaceutical compositions comprising vanoxerine and antianginal compounds, and methods of administration of the same for treating episodes of cardiac arrhythmia, maintaining normal sinus rhythm, preventing recurrence of cardiac arrhythmia, and treatment of chronic cardiac arrhythmia in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
US20210177840A1 (en) 2019-12-16 2021-06-17 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
DK0714660T3 (da) * 1989-06-23 2002-10-07 Syntex Llc Ranolazin og beslægtede piperaziner til beskyttelse af skeletmuskulatur
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
EP1527779A1 (en) 2005-05-04
CY2008020I1 (el) 2010-07-28
FR09C0001I1 (sl) 2009-02-27
NO20054324L (no) 2001-04-30
NO20011191L (no) 2001-04-30
CN1211086C (zh) 2005-07-20
ATE217794T1 (de) 2002-06-15
AU2008207703A1 (en) 2008-09-25
DE69922964D1 (de) 2005-02-03
RU2207856C2 (ru) 2003-07-10
JP2006096757A (ja) 2006-04-13
DK1096937T3 (da) 2005-05-09
EP1109558B1 (en) 2002-05-22
CA2342390C (en) 2006-08-29
AR022085A1 (es) 2002-09-04
US6562826B1 (en) 2003-05-13
HK1040060A1 (en) 2002-05-24
CZ301375B6 (cs) 2010-02-03
NO20011191D0 (no) 2001-03-08
AR052921A1 (es) 2007-04-11
US20060147521A1 (en) 2006-07-06
AU6142599A (en) 2000-03-27
CN1354665A (zh) 2002-06-19
EP1096937B9 (en) 2007-02-28
TR200101262T2 (tr) 2001-12-21
PL196263B1 (pl) 2007-12-31
HK1044284A1 (en) 2002-10-18
NO2009005I1 (no) 2009-03-16
BR9913553A (pt) 2001-10-23
RU2214233C2 (ru) 2003-10-20
CN1321088A (zh) 2001-11-07
US20020004506A1 (en) 2002-01-10
AR053440A2 (es) 2007-05-09
NO20011192L (no) 2001-04-30
NZ510384A (en) 2002-10-25
US20030166659A1 (en) 2003-09-04
TR200101261T2 (tr) 2002-05-21
EP1096937B1 (en) 2004-12-29
US6525057B2 (en) 2003-02-25
US20050059667A1 (en) 2005-03-17
JP2002524416A (ja) 2002-08-06
ES2177346T3 (es) 2002-12-01
SI1109558T1 (sl) 2002-10-31
US6503911B2 (en) 2003-01-07
HUP0103844A3 (en) 2002-11-28
NO319434B1 (no) 2005-08-15
AU6036499A (en) 2000-03-27
IL141893A0 (en) 2002-03-10
CN1193757C (zh) 2005-03-23
US6369062B1 (en) 2002-04-09
WO2000013687A2 (en) 2000-03-16
NO320986B1 (no) 2006-02-20
HUP0104088A2 (hu) 2002-05-29
US20050153982A1 (en) 2005-07-14
HUP0104088A3 (en) 2002-12-28
KR100475759B1 (ko) 2005-03-10
US20040097514A1 (en) 2004-05-20
CA2343376A1 (en) 2000-03-16
WO2000013686A3 (en) 2000-07-06
IL180864A0 (en) 2007-07-04
US6303607B1 (en) 2001-10-16
US20060217397A1 (en) 2006-09-28
GEP20053420B (en) 2005-01-25
EP1109558A2 (en) 2001-06-27
IL141892A (en) 2006-08-20
WO2000013687A3 (en) 2000-06-29
UA67793C2 (uk) 2004-07-15
US6617328B2 (en) 2003-09-09
CA2342390A1 (en) 2000-03-16
US6620814B2 (en) 2003-09-16
JP3745621B2 (ja) 2006-02-15
ES2234302T3 (es) 2005-06-16
BR9913626A (pt) 2001-12-04
IL141892A0 (en) 2002-03-10
CY2008020I2 (el) 2010-07-28
US6864258B2 (en) 2005-03-08
CZ2001879A3 (cs) 2001-08-15
TWI241911B (en) 2005-10-21
US20030099705A1 (en) 2003-05-29
NL300371I2 (nl) 2009-10-01
LU91504I9 (sl) 2019-01-02
NZ510386A (en) 2003-08-29
DE69901570D1 (de) 2002-06-27
PL202207B1 (pl) 2009-06-30
DE69922964T2 (de) 2005-12-08
DE69901570T2 (de) 2003-01-09
US6852724B2 (en) 2005-02-08
PT1109558E (pt) 2002-10-31
FR09C0001I2 (sl) 2009-12-18
NO20011192D0 (no) 2001-03-08
AU2008207707A1 (en) 2008-09-25
MXPA01002598A (es) 2002-04-08
US20020090396A1 (en) 2002-07-11
CZ301341B6 (cs) 2010-01-20
HU224215B1 (hu) 2005-06-28
AU744071B2 (en) 2002-02-14
US20030100566A1 (en) 2003-05-29
LU91504I2 (fr) 2009-02-03
NO2009005I2 (sl) 2010-06-28
CZ2001880A3 (cs) 2001-08-15
KR20010089874A (ko) 2001-10-12
HUP0103844A2 (hu) 2002-04-29
IL175371A0 (en) 2006-09-05
PL196668B1 (pl) 2008-01-31
MXPA01002599A (es) 2005-02-17
EP1096937A2 (en) 2001-05-09
US20040029890A1 (en) 2004-02-12
PT1096937E (pt) 2005-04-29
UA75027C2 (uk) 2006-03-15
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
DK1109558T3 (da) 2002-08-26
DE122008000065I1 (de) 2009-04-09
ATE285774T1 (de) 2005-01-15
NL300371I1 (nl) 2009-02-02
CA2343376C (en) 2007-01-09
PL348249A1 (en) 2002-05-20
AU760435B2 (en) 2003-05-15
IL141893A (en) 2008-08-07
HK1044284B (zh) 2005-07-15

Similar Documents

Publication Publication Date Title
IL175371A0 (en) Sustained release ranolazine formulations
GB9804013D0 (en) Formulations
AU4009201A (en) Sustained release ranolazine formulations
PL343096A1 (en) Sustained release preparations
HUP0103883A3 (en) New sustained release oral formulations
GB9715751D0 (en) Formulations
IL130424A0 (en) Ziprasidone formulations
ZA9810710B (en) Sustained release formulations comprising alpha-glucosidase-inhibitors
GB2334486B (en) Release unit
GB9806312D0 (en) Novel formulations
GB9815002D0 (en) Formulations
GB9815001D0 (en) Formulations
GB9810181D0 (en) Novel formulations
GB9910118D0 (en) Formulations
GB9816563D0 (en) Controlled release formulations
GB9704521D0 (en) Formulations
GB9703101D0 (en) Formulations
GB9703100D0 (en) Formulations
GB9703099D0 (en) Formulations
GB9909080D0 (en) Novel formulations
GB9909079D0 (en) Novel formulations